University of Minnesota. Driven to Discover.
Short-course therapy led to a favorable outcome in 79% of patients, compared with 80% in long-course patients.
The new drug is a 'modernized' version of tetracycline, designed to address antibiotic resistance, but its clinical role isn't yet clear.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.